The influence of molecular alterations on the histology and clinical behavior of follicular cell-derived cancers is reflected in the classification of DTCs into BRAF-like and RAS-like, in addition to a third group of non-BRAF-/non-RAS-like tumors [7,8]. The gene discussed is BRAF; the disease is cancer.